Novartis Receives FDA Priority Review for Kidney Drug Fabhalta

FDA grants Priority Review for Novartis's Fabhalta, based on data showing a 49.3% reduction in kidney function decline, aiming for full approval.

Novartis has taken a significant step toward expanding the use of its kidney disease therapy, Fabhalta, after U.S. regulators granted it a Priority Review designation. This accelerated FDA assessment follows the release of compelling long-term clinical data that underscores the drug's potential.

Robust Clinical Data Supports Application

The foundation for this regulatory milestone is the final data from the Phase III APPLAUSE-IgAN trial. Published in the New England Journal of Medicine, the study demonstrated that Fabhalta significantly slowed kidney function decline in patients with a chronic kidney disease. Over a two-year period, the progression of kidney function loss, measured by the estimated glomerular filtration rate (eGFR), was reduced by 49.3% compared to a placebo. Investigators noted that the treatment's safety profile remained consistent throughout the trial.

Currently, Fabhalta holds an accelerated approval in the United States and China, but its use is limited to reducing proteinuria, or protein in the urine. The new application seeks a full, regular approval based on the hard clinical outcome of delaying kidney function decline. The Priority Review status substantially shortens the FDA's evaluation timeline, positioning the drug for a potential broader label and a more central role in Novartis's nephrology portfolio.

Market Reaction and Strategic Importance

Trading on Monday reflected cautious investor optimism. Novartis shares advanced by 0.87 percent to close at 130.12 euros. This modest gain hints at a possible stabilization for the stock, which had declined approximately 8.5 percent over the preceding 30-day period. Despite the uptick, the share price remains slightly below its 50-day moving average of 132.56 euros.

The impending FDA decision, expected in the coming months, represents a pivotal event for Novartis. A successful conversion to a regular approval, anchored by the 49.3% efficacy data, would transform Fabhalta from a specialized treatment into a cornerstone of the company's global kidney disease strategy. This would enable a substantial expansion of its market reach and commercial potential.